Fig. 2. Multiparametric magnetic resonance imaging reports (PI-RADSv.2) and prostate biopsy results regarding the proposed algorithm in men with suspected PCa, based on serum PSA >3.0 ng/mL and/or abnormal DRE, in whom mpMRI and guided and/or systematic biopsies were performed. PCa: prostate cancer, mpMRI: multiparametric magnetic resonance imaging, DRE: digital rectal examination, PSA: prostate-specific antigen, csPCa: clinically significant PCa, iPCa: insignificant PCa.